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Type 1 (Th1) granulomas can be studied in mice sensitized with mycobacterium
antigens followed by challenge of agarose beads covalently coupled to purified protein
derivative. TLR9 is known to play a role in the regulation of Th1 responses; thus, we
investigated the role of TLR9 in granuloma formation during challenge with
mycobacterium antigens and demonstrated that mice deficient in TLR9 had increased
granuloma formation, but a dramatically altered cytokine phenotype. Th1 cytokine
levels of IFN-c and IL-12 in the lungs were decreased inTLR9–/– mice when compared to
wild-typemice. In contrast, Th2 cytokine levels of IL-4, IL-5, and IL-13 were increased in
TLR9–/– mice. The migration of CD4+ T cells in the granuloma was impaired, while the
number of F4/80+ macrophages was increased in TLR9–/– mice. Macrophages in the
lungs of the TLR9-deficient animals with developing granulomas expressed
significantly lower levels of the classically activated macrophage marker, nitric oxide
synthase, but higher levels of the alternatively activated macrophage markers such as
'found in inflammatory zone-10 antigen and Arginase-1. These results suggest that TLR9
plays an important role in maintaining the appropriate phenotype in a Th1
granulomatous response.
Introduction
The lung is one of the most immunologically challenged
organs and can be affected by a number of granuloma-
inducing agents including non-infectious environmental
factors and infectious mycobacteria, fungi, and parasites
[1, 2]. Among these, tuberculosis, a lung disease caused
by Mycobacterium tuberculosis, remains a significant
cause of morbidity and mortality throughout the world
[3]. A granuloma, composed of a group of epithelioid
macrophages surrounded by a lymphocyte cuff, is a
characteristic pathophysiological feature induced by
mycobacterial infections and is an important element of
the host defense system [2, 4]. Interestingly, little is
known about the immunological and pathological
mechanisms that control granuloma formation in the
lung. We previously described a model of polarized Th1
cell-mediated anamnestic pulmonary granulomatous
inflammation in sensitized mice induced by pulmonary
embolization of agarose beads coated with covalently
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bound antigens of Mycobacteria bovis purified protein
derivative (PPD) [5–9]. Cytokine and chemokine
analyses of this model indicated protein profiles
consistent with a predominant Th1 cell involvement
and histologically showed an enrichment of macro-
phages at the granuloma sites [10, 11].
Macrophages become activated and express distinct
patterns of chemokine and cytokines in response to
exogenous signals such as pathogen byproducts and
soluble immune mediators. They can be activated by
either a classical (M1) or alternative (M2) pathway
depending on the stimulus [12, 13]. M1 macrophages,
induced by proinflammatory molecules such as IFN-c
and LPS, play an important role in the elimination of
various pathogens [14]. They up-regulate the expression
of proinflammatory cytokines (TNF-a, IL-12) and are
able to secrete nitric oxide (NO), a free radical that is
toxic to bacteria and other pathogens, via activation of
inducible NO synthase (iNOS) [15]. M2 macrophages
are activated in response to the Th2 cytokines, IL-4 and
IL-13 [16], and are functionally and biochemically
distinct from M1 macrophages [17]. They produce low
levels of proinflammatory cytokines, and fail to produce
NO [17]. Instead, arginase production and induction of
FIZZ-1 (found in inflammatory zone-1) are increased
[18, 19]. It has been demonstrated that M2macrophages
are generated during the development of Th2 granulo-
mas, for example those elicited by Schistosoma mansoni
eggs, and the M2 macrophages down-modulated Th1
responses [20]. However, the precise mechanisms that
regulate M1 and M2 activation within the context of
granuloma formation remain to be determined.
Macrophages respond to microbial ligands through
TLR [21], which are key molecules in the recognition of
microbial components during infection and are known
to play an important role in both the innate and adaptive
immune response [22–24]. Microbial products, includ-
ing mycobacterium antigen, activate specific TLR, which
in turn induce specific gene transcription resulting in the
up-regulation and secretion of select chemokines and
cytokines [25–27]. When activated, TLR specifically
recruit adapter proteins (MyD88, MAL, TRIF, TRAM,
and SARM), which are essential for the TLR gene
transcription signaling cascade [28, 29]. Recent studies
have provided new insights on how TLR are involved in
the recognition of specific pathogens, and have clarified
their roles in both the innate and adaptive immune
response. For example, mycobacterial components act as
agonists for TLR, and mice that are deficient in the TLR
adaptor molecule, MyD88, show an impaired response
to mycobacterial antigens, which is correlated with
decreased NOS2 expression and decreased IFN-c
production [30]. Although the response to mycobac-
terium antigens appears dependent on MyD88 [30, 31],
the TLR involved has not been identified. All TLR, except
TLR3, have at least one signaling pathway dependent on
MyD88 [22]. The involvement of different TLR, for
example, TLR2, TLR4, and TLR6, in the recognition of
mycobacterium antigens has been shown in mice and
humans [25, 32–37]. TLR9 recognizes as ligands viral
and bacterial CpG-DNA motifs, which when bound to
TLR9 on macrophages and DC, causes their activation
[38–40]. A number of studies indicate that CpG-DNA
TLR9 interaction can drive a Th1 immune response, as
evidenced by a Th1-dominated cytokine profile [41–43].
A recent report demonstrated that TLR9 played an
important role in the regulation of the mycobacteria-
induced Th1 responses during M. tuberculosis infection
in vivo [44]. Although these studies showed the
importance of TLR9 in driving the Th1 response to
microbial infection, none investigated the role of TLR9
in pulmonary granuloma formation during mycobacter-
ium antigen challenge.
In the present study, Th1 cytokines and chemokine
[IFN-c, IL-12, and IFN-c-inducible protein 10, (IP-10)]
and Th2 cytokines (IL-4, IL-5, and IL-13) profiles were
determined in both WT and TLR9–/– mice using a PPD
bead-induced experimental lung granuloma model. We
demonstrate that TLR9-deficient mice developed a type-
2-like response with significantly larger granulomas and
increased accumulation of eosinophils compared to
control mice granulomas. This greater granulomatous
and enhanced eosinophilic response was associated with
a selectively abrogated type-1 and enhanced type-2
cytokine profile in the lung. We also found that the
recruitment of CD4+ T cells to granulomas was
impaired, while increased numbers of F4/80+ macro-
phages were observed. Our results further showed that
lung macrophages were shifted from classically acti-
vated (M1) to alternatively activated (M2) in TLR9–/–
mice. Taken together, our data support the premise that
TLR9 plays a key role in the induction of a Th1 cell-
mediated hypersensitive granuloma formation.
Results
Effect on TLR9 gene knockout on pulmonary
granuloma size and composition
To investigate the role of TLR9 on the effector stage of
antigen-bead elicited responses, mice were sensitized
i.p. with 0.5 mL CFA and 14 days later were challenged
via a tail vein with PPD-coupled beads. The beads
embolize to the lungs where they elicit a synchronous
granulomatous inflammatory response that spreads into
the interstitium and is histologically similar to those
observed in live mycobacterium infections. We charac-
terized the histology of antigen bead-challenged lungs
throughout an 8-day period following injection of the
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beads. The antigen-induced response in the TLR9–/–
mice showed significantly larger granulomas compared
with WT mice on day 2 (Fig. 1A and B), day 4 (Fig. 1C
and D), and day 8 (Fig. 1E and F). The size was the
largest on day 4 in both WT and TLR9–/– mice, and the
differences between these mice were significant on
day 2 (5800.4  1510.7 lm2 vs. 8376.2  1736.5 lm2),
day 4 (8086.7  1811.6 lm2 vs. 13061.6 3016.6 lm2)
and day 8 (5442.2  1375.6 lm2 vs. 8549.1 
1957.8 lm2) (WT vs. TLR9–/– mice, respectively)
(Fig. 2). Histologically, TLR9–/– mice displayed in-
creased eosinophils in lung granulomas compared with
WT mice at day 8 (Fig. 3A). Upon quantification,
eosinophils in lung granulomas were significantly
higher in TLR9–/– (0.589  0.232/100 lm2) compared
with in WT mice (0.099  0.062/100 lm2) (Fig. 3B).
Alternation in the cytokine and chemokine profile
in whole lungs from TLR9–/– mice
To help elucidate themechanism underlying the changes
in pulmonary granuloma size and cellular content in
TLR9–/– versus WT mice, we profiled cytokine and
chemokine expression in lungs. In the present study,
whole lungs from TLR9–/– mice had significantly lower
levels of both mRNA and protein of IFN-c and IP-10, in
comparison with WT mice (Fig. 4A–D). Moreover, the
cytokine profile in the whole-lung samples revealed a
significant decrease in IL-12p70 protein level in TLR9–/–
mice at days 2 and 4 after PPD bead challenge (Fig. 4F).
IL-12 is a heterodimeric cytokine, consisting of cova-
lently bound p40 and p35 subunits, and TLR9–/– mice
showed lower mRNA levels for both of these subunits
Figure 1. Histological appearance of pulmonary granulomas
induced by PPD beads. Lung tissue from WT (A, C, and E) and
TLR9–/– mice (B, D, and F) was analyzed 2, 4, and 8 days after i.v.
injectionwith 5500 PPD beads. H&E-stained lung sections from
WT or TLR9–/– mice are shown (magnification, 400); n=5
animals/time point/group.
Figure 2. Time course of innate granulomatous inflammation
in response to PPD-coated agarose beads during an 8-day study
period. Points are mean granuloma cross-sectional area
(lm2)  SEM with five mice per point and with 20 granulomas
measured per lung. The dotted line indicates average size of
bead only. *p<0.001 comparedwith granuloma size measure in
WT mice.
Figure 3. Increased number of eosinophils in TLR9–/– mice
during granuloma formation. Lung tissue from WT (A) and
TLR9–/– (B) mice was analyzed at 8 days after PPD-bead
challenge. High-power micrographs of lung sections of
TLR9–/– mice display aggregation of eosinophils around PPD
bead (magnification,1000). No eosinophils were detected 2 or
4 days post injection. (C) Quantification of eosinophil numbers
in pulmonary granulomas. Granulomas, 20 per mouse, were
analyzed for the eosinophil infiltrate. Results are expressed as
mean  SEM per 100 lm2 area in granuloma from five mice/
group using computerized morphometry. *p<0.001 versus WT.
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compared to WT mice (Fig. 4E and G). While TLR9–/–
mice showed a defect in Th1 cytokine and chemokine
production in response to PPD beads, mRNA and protein
levels of cytokines that promote the Th-2 biased immune
response (i.e., IL-4, IL-5 and IL-13), were significantly
increased in TLR9–/– mice (Fig. 5A, C, and E). ELISA
analysis confirmed that the protein level of IL-4 and IL-5
was increased at 8 days after bead challenge (Fig. 5B
and D), and that IL-13 was higher throughout the 8-day
period in TLR9–/– mice (Fig. 5F).
Decreased recruitment of CD4+ T cells in TLR9–/–
mice
Flow cytometric analysis revealed that the number of
CD3+CD4+ T cells was severely decreased (Fig. 6A),
while the number of F4/80+ macrophages was in-
creased inTLR9-deficient lungs at 4 days after PPD-bead
challenge (Fig. 6B). These results were also supported
by immunohistochemical analysis. (Fig. 6C and D),
which shows more F4/80+ staining cells and a decrease
in CD4+ cells associated with the local lung granuloma.
TLR9–/– mice demonstrated a M2 macrophage
phenotype during pulmonary granuloma
formation
Because the number of macrophages in the pulmonary
granulomas was increased in TLR9–/– mice, we assessed
the phenotype of the granuloma evolving in WT and
TLR9–/– mice for macrophage markers characteristic of
either an M1 or M2 response. The mRNA expression
level of iNOS, which is a macrophage marker for an M1
phenotype, was significantly less in TLR9–/– mice
(Fig. 7A). In contrast, the mRNA expression level of
M2 markers FIZZ-1 and Arginase-1 were significantly
increased in TLR9–/– mice compared with WT mice
(Fig. 7B and C). These data support the functionality of
the Th2 cytokine expression profile, which predomi-
nates in the TLR9–/– mice even when challenged with
antigen known to induce a classic IFN-c response.
Figure 4. TLR9–/– mice show impaired Th1 chemokine and
cytokine levels both in transcript expression and in protein
production. On days 0, 2, 4, and 8, total RNAwas isolated and
reverse transcribed to cDNA. Quantitative real-time PCR
(Taqman) was performed to measure the transcript levels of
each cytokine. The transcript expression of Th1 cytokines and
chemokines, IFN-c (A), IP-10 (C), IL-12p35 (E), and IL-12p40 (G),
was measured. The protein level of IFN-c (B), IP-10 (D), and
IL-12p70 (F) was determined in the whole lungs from mice of
WT and TLR9-deficient group by ELISA. The cytokine and
chemokine levels in each whole-lung sample were normalized
to total protein levels measured using the Bradford assay. Bars
are mean  SD for four to six individual lungs per point. Data
are combined studies of three independent experiments.
*p<0.05, **p<0.01 compared with WT.
Figure 5. TLR9–/– mice exhibit enhanced Th2 cytokine level
both in transcript expression and in protein production. The
gene expression level of IL-4 (A), IL-5 (C), and IL-13 (E) in the
whole lungs at days 0, 2, 4, and 8 after PPD-bead challenge is
shown. mRNA levels were quantitated as described (Materials
and methods and Fig. 4 legend). The protein level of IL-4 (B), IL-5
(D), and IL-13 (F) was determined in thewhole lungs frommice
of WT and TLR9-deficient group by ELISA as described
(Materials and methods and Fig. 4 legend). Bars are mean  SD
for four to six individual lungs per point. Data are combined
studies of three independent experiments. *p<0.03, **p<0.01
compared with WT.
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Discussion
Our results demonstrate that the TLR9 signaling path-
way is essential in the regulation of the Th1 granuloma
response to mycobacterial antigens. To our knowledge,
the present investigation represents the first analysis of
cell-mediated Th1 pulmonary granuloma formation in
mice with targeted disruption of the TLR9 gene. Our
study demonstrated that TLR9-deficient mice exhibited
significantly larger granuloma formation with a higher
eosinophil content, suggesting a shift to a Th2-like
response. These histological findings in TLR9–/– mice
coincided with significantly decreased whole-lung
IFN-c, IP-10 and IL-12 levels and significantly increased
whole-lung levels of IL-4, IL-5, and IL-13 during the
formation and maintenance of the granuloma responses
when compared with WT mice.
Pulmonary granuloma formation is initiated by a
number of infectious and non-infectious agents, and
previous studies have illustrated the importance of
distinct profiles of cytokines and chemokines in defining
the type and predicting sequelae of the granulomatous
response [7, 8]. Specifically, the embolization of
Sepharose beads coated with PPD from M. tuberculosis
initiates a Thl-type immune response that is character-
ized by IFN-c and IL-12 expression [7]. IL-12 is a key
cytokine that promotes IFN-c production and is known
to augment Th1 cell-mediated immune reactions [45],
while IFN-c is essential for the elimination of myco-
bacteria [46, 47]. Our studies showed impaired expres-
sion of IFN-c and IL-12 in TLR9–/– mice, as well as larger
Th2-like granulomas when compared to WT mice,
suggesting the pivotal role commanded by TLR9 in
driving the Th1-mediated immune response to myco-
bacterial antigen. In studies using IL-12-knockoutmice a
decrease in the IFN-c response and an increased
susceptibility of mice to mycobacterium challenge was
Figure 6. The recruitment of impaired CD4+ T cells and
enhanced F4/80+ macrophages during pulmonary granuloma
formation in TLR9–/– mice. (A, B) The FACS profiles of lung cells
isolated from day 4 PPD-bead challenged mice. Mice killed at
day 0 did not receive PPD-beads and were used as baseline
values. Lungs were digested by collagenase IV, and the
dispersed cells were stained as follows: CD3+CD4+ (A) and
F4/80+ (B). The results shown are representative of two
experiments and are expressed as mean  SEM; n=4–5 lung
samples per group out of two independent experiments.
*p<0.02, and **p<0.01. (C, D) Immunohisitochemical examina-
tion of pulmonary granuloma showed fewer CD4+ cells and
increased F4/80+ cells in TLR9–/– mice. Dotted lines indicate the
area where PPD-beads existed before being washed out by
immunohistochemical staining procedure. Cryostat sections
were obtained from day 4 bead-challenged lungs and stained
for CD4 (C) and F4/80 (D) as described in Materials and Methods
(magnification, 400).
Figure 7. Decreased M1 markers and increased M2 markers
during PPD-bead challenge in TLR9–/– mice. The gene expres-
sion level of iNOS (A), FIZZ-1 (B) andArginase-1 (C) in thewhole
lungs at days 0, 2, 4, and 8 after PPD-bead challenge is shown.
mRNA levels were quantitated as described (Materials and
methods and Fig. 4 legend). TLR9–/– mice exhibited lower
transcript level of M1 markers (iNOS), but higher level of M2
markers (FIZZ-1 and Arginase-1). Bars are mean  SD for four
to six individual lungs per point. Data are combined studies of
three independent experiments. *p<0.02, **p<0.01 compared
with WT.
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observed [48–50], supporting our findings that TLR9–/–
mice have larger granulomas with decreased levels of
IFN-c and IL-12. Previous studies indicated that in
IFN-c-deficient mice the type 1 granuloma cytokine
profile is shifted to a type 2 pattern [51]: this shift was
also observed in our model. TLR9 deficiency increased
expression of Th2 cytokines IL-4, IL-5, and IL-13 while
significantly decreasing the production of IFN-c. IL-4
operates as the key cytokine driving the type-2 response
[52], IL-5 induces the recruitment of eosinophils [53],
and IL-13 is a pleiotropic cytokine produced predomi-
nantly by CD4+ Th2 cells. IL-13 is an IL-4-related
cytokine, and its receptor contains the IL-4 receptor
a1-chain signaling component [54]. IL-13 provides
regulatory support to Th2 responses [55], and we have
previously demonstrated that antibody-mediated IL-13
depletion increased transcript levels of IFN-c in a model
of Th1-mediated mycobacterial antigen-induced pul-
monary granuloma formation [6]. During M. tuber-
culosis infection, TLR9 regulates the Th1 response
through IFN-c and IL-12 production [44]. These studies
are consistent with our data showing lower Th1 and
higher Th2 cytokine levels during pulmonary granuloma
formation in TLR9–/– mice. In contrast to our results
showing greater granuloma size in our TLR9–/– model,
the study of Bafica and colleagues [44] neither assessed
alternations in granuloma pathology nor did they
perform a detailed analysis of a model of synchronized
inflammation.
In the present study we again demonstrate that
macrophages play an important role in granuloma
formation. In vitro, macrophage activation has been
operationally defined across two distinct polarization
states, defined as either an M1 or M2 phenotype [13,
16]. However, in vivo a continuum between these two
states more likely exists. Classically activated (M1)
macrophages are prototypical immune effector cells that
kill intracellular pathogens via the production of oxygen
and nitrogen radicals [56]. These cells also secrete a
series of proinflammatory cytokines, which help to
orchestrate and amplify Th1 immune responses [57]. A
second population of macrophages or alternatively
activated (M2) macrophages arises in response to an
environment dominated by Th2 cytokines, IL-4 and/or
IL-13, and they are functionally distinct from M1
macrophages. They fail to produce NO, but they up-
regulate mannose receptor expression [17]. They
express several unique markers such as FIZZ-1 and
Ym1, which are not found on M1 macrophages [19]. It
has been proposed that the in vivo induction of FIZZ-1 in
macrophages depends on IL-4 [19]. Additionally,
arginase production is significantly increased in M2-
polarized macrophages. This enzyme blocks iNOS
activity by a variety of mechanisms, including competing
for the arginase substrate that is required for NO
production [58]. We have demonstrated in this study
that the lungs of TLR9–/– mice showed decreased iNOS
expression and increased expression of FIZZ-1 and
Arginase-1; characteristic of M2 skewing. Our data
showing larger granuloma formation in TLR9–/– mice
are also consistent with previous study showing that
increased NO played a protective role during lung
inflammation, and inhibition of NO synthesis during
PPD-bead granuloma formation resulted in a change in
granuloma size and cellular morphology [59, 60]. The
investigation described in this manuscript affirmed the
key role of TLR9 in determining macrophage phenotype,
as a shift from M1 to M2 macrophages occurred in
TLR9–/– mice. Relatedly, another study reported that M2
macrophages failed to stimulate efficient T cell prolif-
eration [57]. We showed here that IP-10 (CXCL10), a
chemokine that promotes the migration of activated
T cells (Th1 lymphocytes) [61], was decreased in
TLR9–/– mice. This finding might underlie the impaired
recruitment of CD4+ T cells towards granulomas in
TLR9–/– mice.
In summary, we present a comprehensive in vivo
analysis of TLR9 participation, using TLR9–/– mice, in a
model of Th1 granuloma formation induced by
mycobacteria-associated antigens. Similar to the IFN-c
knockout mouse [51], TLR9 deficiency resulted in
decreased Th1 and increased Th2 cytokine profiles
during pulmonary granuloma formation, and led to an
accelerated granulomatous response characterized by
increased eosinophils. This was associated with de-
creased CD4+ T cells, enhanced macrophage recruit-
ment, and a significant skewing towards an M2
phenotype. This study supports the concept that an
impaired type-1 cytokine profile in TLR9-deficient lungs
is a major consequence of larger granuloma formation.
Materials and methods
Mice
Mice (BALB/c) lacking the TLR9 gene (TLR9–/–) were provided
by Theodore J. Standiford, M.D., University of Michigan
Medical School. WTcontrol BALB/c mice were purchased from
The Jackson Laboratories (Bar Harbor, ME). All mice were
maintained under specific pathogen-free conditions and
provided with food and water ad libitum in the University
Laboratory Animal Medicine (ULAM) facility at the University
of Michigan Medical School. All animal protocols were
approved by ULAM.
Antibodies
Rat mAb specific for mouse CD3 (17A2), CD4 (L3T4), CD16/
32 (2.4G2), CD45 (30-F11) was purchased from BD PharMin-
gen (San Diego, CA). Rat Anti-F4/80 (CI: A3–1) mAb was
purchased from Serotec (Raleigh, CA).
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Sensitization and granuloma induction
Type 1 lung antigen-bead granulomas were generated as
follows. Mice were sensitized i.p. with complete Freund's
adjuvant (CFA) (Sigma-Aldrich, St. Louis, MO). After
14–16 days, mice were challenged i.v. with 5500 Sepharose
4B beads (in 0.5 mL PBS) covalently coupled to PPD, as
previously described [5]. Mice were killed 2, 4, or 8 days after
i.v. injection. This model results in a well-circumscribed lung
granuloma typified by a type 1 cytokine phenotype.
Morphometry
Individual excised lung lobes were inflated and fixed with 10%
buffered formalin for morphometric analysis. The areas of the
granulomas were measured in a blinded fashion on H&E-
stained sections of paraffin-embedded lungs using computer-
assistedmorphometry as previously described [62]. Eosinophil
recruitment to the lung granuloma was quantitated and
normalized to the granuloma size. A minimum of 20
granulomas per lung section was analyzed for granuloma
size, and 20 granulomas per mouse were analyzed for the
eosinophil infiltrate [62].
Reverse transcription and real-time quantitative PCR
analysis
Total RNA was isolated from whole lungs using TRIzol
(Invitrogen Corporation, Carlsbad, CA) according to manu-
facturer's instructions. Briefly, 2.0 lg RNA was reverse
transcribed to yield cDNA in a 25-lL reaction mixture
containing 1 first strand (Life Technologies, Gaithersburg,
MD), 250 ng oligo(dT) primer, 1.6 mmol/L dNTPs (Invitro-
gen), 5 U RNase inhibitor (Invitrogen), and 100 U Moloney
murine leukemia virus reverse transcriptase (Invitrogen) at
38C for 60 min; and the reaction was stopped by incubating
the cDNA at 94C for 10 min. Real-time quantitative PCR
analysis was performed using an ABI 7700 sequence detector
system (PE Applied Biosystems, Foster City, CA). The thermal
cycling conditions included 50C for 2 min and 95C for
10 min, followed by 40 cycles of amplification at 95C for 15 s
and 55C for 1.5 min for denaturing and annealing, respec-
tively.
ELISA analysis of chemokine and cytokine expression
Murine IP-10, IL-4, IL-5, IL-12, IL-13, and IFN-c levels were
measured in 50 lL samples from whole lung homogenates
using a standardized sandwich ELISA technique previously
described in detail [63]. The limit of detection for all ELISAwas
approximately 50 pg/mL. The chemokine and cytokine levels
in each sample were normalized to the protein (in milligrams)
present in cell-free preparation of each sample measured by
the Bradford assay, as described previously [62].
Flow cytometry
Flow cytometric analyses of lung cells were performed as
previously described [62]. Briefly, whole lungs were dispersed
in 0.2% collagenase (Sigma-Aldrich) in RPMI 1640 (Mediateck
Inc., Herndon, VA) and 5% FBS (Atlas, Fort Collins, CO) at
37C for 45 min. The cells were stained with FITC-conjugated
anti-CD4 mAb and PE-conjugated anti-CD3 mAb for 15 min.
CD3+CD4+ T cells were determined by flow cytometry after
gating lymphocyte populations by forward and scatter
parameters. In some experiments, cells were stained with
PE-conjugated anti-F4/80. The percentage of macrophages
was determined as percentage of CD45+F4/80+ lung cells.
Immunohistochemistry
Mice were killed 4 days after i.v. injection of Sepharose 4B
beads covalently coupled to PPD. Acetone-fixed 7-lm cryostat
sections were incubated with purified rat mAb specific for
mouse anti-CD4 or anti-F4/80 with detection using a Cell and
Tissue Staining kit (R&D Systems,Minneapolis, MN) according
to manufacture's instructions, followed by color development
with HRP-DAB System (R&D Systems).
Statistical analysis
Statistical analysis was performed using Student's t-test. The
95% confidence limit was determined significant.
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